News & Events

A comprehensive analysis of patients with cancer who had exceptional responses to therapy has revealed molecular changes in the patients’ tumors that may explain some of the exceptional responses.

NCI and the National Institute of Biomedical Imaging and Bioengineering have awarded seven contracts to develop digital health solutions, like smartphone apps, wearable devices, and software, that help address the COVID-19 pandemic.

NCI and Cancer Research UK will partner to fund Cancer Grand Challenges, an international initiative to address profound and unanswered questions in cancer research.

Mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment, an NCI study shows.

In a new study, an automated dual-stain method using artificial intelligence improved the accuracy and efficiency of cervical cancer screening compared with the current standard for follow-up of women who test positive with primary HPV screening.

The new test is relatively simple and could improve screening for people who are at risk for developing hepatocellular carcinoma (HCC), the most common form of liver cancer. It could help doctors find and treat HCC early.

As described in an NCI Media Availability, early data from a clinical study suggest that treatment with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.

In an NCI study, an alternative treatment regimen called dose-adjusted EPOCH-R that is less toxic than standard dose-intensive chemotherapy was highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status.

In a new study, higher daily step counts were associated with lower mortality risk from all causes. Researchers found that the number of steps taken each day, but not the intensity of the stepping, had a strong association with mortality.

Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.